Interactions Between the Canonical WNT/Beta-Catenin Pathway and PPAR Gamma on Neuroinflammation, Demyelination, and Remyelination in Multiple Sclerosis
- 438 Downloads
Multiple sclerosis (MS) is marked by neuroinflammation and demyelination with loss of oligodendrocytes in the central nervous system. The immune response is regulated by WNT/beta-catenin pathway in MS. Activated NF-kappaB, a major effector of neuroinflammation, and upregulated canonical WNT/beta-catenin pathway positively regulate each other. Demyelinating events present an upregulation of WNT/beta-catenin pathway, whereas proper myelinating phases show a downregulation of WNT/beta-catenin pathway essential for the promotion of oligodendrocytes precursors cells proliferation and differentiation. The activation of WNT/beta-catenin pathway results in differentiation failure and impairment in remyelination. However, PI3K/Akt pathway and TCF7L2, two downstream targets of WNT/beta-catenin pathway, are upregulated and promote proper remyelination. The interactions of these signaling pathways remain unclear. PPAR gamma activation can inhibit NF-kappaB, and can also downregulate the WNT/beta-catenin pathway. PPAR gamma and canonical WNT/beta-catenin pathway act in an opposite manner. PPAR gamma agonists appear as a promising treatment for the inhibition of demyelination and the promotion of proper remyelination through the control of both NF-kappaB activity and canonical WNT/beta-catenin pathway.
KeywordsCanonical WNT/beta-catenin pathway PPAR gamma Multiple sclerosis PI3K/Akt pathway Demyelination Remyelination Inflammation TCF7L2
Adenomatous polyposis coli
Glycogen synthase kinase-3beta
- LRP 5/6
Low-density lipoprotein receptor-related protein 5/6
Phosphatidylinositol 3-kinase-protein kinase B
- PPAR gamma
Peroxisome proliferator-activated receptor gamma
T cell factor/lymphoid enhancer factor
We would like to thank Dr Christophe Locher, President of the “Fédération de la Recherche Clinique du Grand Hôpital de l’Est Francilien,” and Mr. Vincent Gobert, Administrative Manager of the Clinical Research Center, Meaux Hospital, Meaux, France, for their valuable support in making the necessary research facilities available for this study.
All authors listed, have made substantial, direct, and intellectual contribution to the work, and approved it for publication. AV, JNV, RG, and YL have contributed to this review.
Compliance with Ethical Standards
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial, financial relationship, or non-financial interest that could be construed as a potential conflict of interest.
- Benedusi V, Martorana F, Brambilla L et al (2012) The peroxisome proliferator-activated receptor γ (PPARγ) controls natural protective mechanisms against lipid peroxidation in amyotrophic lateral sclerosis. J Biol Chem 287:35899–35911. doi: 10.1074/jbc.M112.366419 PubMedPubMedCentralCrossRefGoogle Scholar
- De Nuccio C, Bernardo A, Cruciani C et al (2015) Peroxisome proliferator activated receptor-γ agonists protect oligodendrocyte progenitors against tumor necrosis factor-alpha-induced damage: effects on mitochondrial functions and differentiation. Exp Neurol 271:506–514. doi: 10.1016/j.expneurol.2015.07.014 PubMedCrossRefGoogle Scholar
- Diab A, Hussain RZ, Lovett-Racke AE et al (2004) Ligands for the peroxisome proliferator-activated receptor-gamma and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis. J Neuroimmunol 148:116–126. doi: 10.1016/j.jneuroim.2003.11.010 PubMedCrossRefGoogle Scholar
- Duvanel CB, Honegger P, Pershadsingh H et al (2003) Inhibition of glial cell proinflammatory activities by peroxisome proliferator-activated receptor gamma agonist confers partial protection during antimyelin oligodendrocyte glycoprotein demyelination in vitro. J Neurosci Res 71:246–255. doi: 10.1002/jnr.10471 PubMedCrossRefGoogle Scholar
- Klotz L, Schmidt M, Giese T et al (2005) Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J Immunol 175:4948–4955PubMedCrossRefGoogle Scholar
- Liu J, Farmer SR (2004) Regulating the balance between peroxisome proliferator-activated receptor gamma and beta-catenin signaling during adipogenesis. A glycogen synthase kinase 3beta phosphorylation-defective mutant of beta-catenin inhibits expression of a subset of adipogenic genes. J Biol Chem 279:45020–45027. doi: 10.1074/jbc.M407050200 PubMedCrossRefGoogle Scholar
- Luna-Medina R, Cortes-Canteli M, Alonso M et al (2005) Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J Biol Chem 280:21453–21462. doi: 10.1074/jbc.M414390200 PubMedCrossRefGoogle Scholar
- Padden M, Leech S, Craig B et al (2007) Differences in expression of junctional adhesion molecule-A and beta-catenin in multiple sclerosis brain tissue: increasing evidence for the role of tight junction pathology. Acta Neuropathol 113:177–186. doi: 10.1007/s00401-006-0145-x PubMedCrossRefGoogle Scholar
- Paintlia AS, Paintlia MK, Singh I, Singh AK (2006) IL-4-induced peroxisome proliferator-activated receptor gamma activation inhibits NF-kappaB trans activation in central nervous system (CNS) glial cells and protects oligodendrocyte progenitors under neuroinflammatory disease conditions: implication for CNS-demyelinating diseases. J Immunol 176:4385–4398PubMedCrossRefGoogle Scholar
- Raikwar HP, Muthian G, Rajasingh J et al (2006) PPARgamma antagonists reverse the inhibition of neural antigen-specific Th1 response and experimental allergic encephalomyelitis by ciglitazone and 15-deoxy-Delta 12,14-prostaglandin J2. J Neuroimmunol 178:76–86. doi: 10.1016/j.jneuroim.2006.05.013 PubMedCrossRefGoogle Scholar
- Ricote M, Huang J, Fajas L et al (1998a) Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 95:7614–7619PubMedPubMedCentralCrossRefGoogle Scholar
- Saegusa M, Hashimura M, Kuwata T et al (2007) Crosstalk between NF-kappaB/p65 and beta-catenin/TCF4/p300 signalling pathways through alterations in GSK-3beta expression during trans-differentiation of endometrial carcinoma cells. J Pathol 213:35–45. doi: 10.1002/path.2198 PubMedCrossRefGoogle Scholar
- Schulman IG, Shao G, Heyman RA (1998) Transactivation by retinoid X receptor-peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimers: intermolecular synergy requires only the PPARgamma hormone-dependent activation function. Mol Cell Biol 18:3483–3494PubMedPubMedCentralCrossRefGoogle Scholar
- Shim CY, Song B-W, Cha M-J et al (2014) Combination of a peroxisome proliferator-activated receptor-gamma agonist and an angiotensin II receptor blocker attenuates myocardial fibrosis and dysfunction in type 2 diabetic rats. J Diabetes Investig 5:362–371. doi: 10.1111/jdi.12153 PubMedCrossRefGoogle Scholar